Elsevier

Clinics in Dermatology

Volume 21, Issue 5, September–October 2003, Pages 392-397
Clinics in Dermatology

Changing paradigms in dermatology: tumor necrosis factor alpha (tnf-α) blockade in psoriasis and psoriatic arthritis

https://doi.org/10.1016/j.clindermatol.2003.08.015Get rights and content

Abstract

Psoriasis is an inflammatory T cell-mediated disease characterized by epidermal hyperplasia and parakeratosis, resulting in lesional areas of thick and scaling skin. Elevated levels of proinflammatory cytokines, including TNF-alpha, are found in psoriatic lesions. TNF-alpha has many effects in producing an inflammatory response such as stimulating production of pro-inflammatory molecules (eg, IL-1, IL-6, IL-8, NF-κB) and adhesion molecules (eg, ICAM-1, P-selectin, E-selectin). As such, TNF-alpha is a target for immunotherapy in the treatment of psoriasis and psoriatic arthritis. The role of TNF-alpha in the pathogenesis of psoriasis is reviewed, along with clinical trials demonstrating the efficacy of new anti-TNF-alpha immunobiologics in the treatment of psoriasis and psoriatic arthritis.

References (48)

  • V. Kainulainen et al.

    Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-α

    J Biol Chem

    (1996)
  • H. Fujisawa et al.

    Interleukin-1 and lipopolysaccharide enhance intercellular adhesion molecule-1 expression in cell lines of human squamous cell carcinoma

    J Dermatol Sci

    (1997)
  • I. Kimber et al.

    Cytokine regulation of chemical sensitization

    Toxicol Lett

    (1995)
  • K. Schwarzenberger et al.

    Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ

    J Invest Dermatol

    (1996)
  • A. Osada et al.

    Up-regulation of CD44 expression by tumor necrosis factor-α is neutralized by interleukin-10 in Langerhans cells

    J Invest Dermatol

    (1995)
  • H. Mizutani et al.

    Role of increased production of monocytes TNF-α, IL-1β, and IL-6 in psoriasisrelation to focal infection, disease activity and responses to treatments

    J Dermatol Sci

    (1997)
  • Z. Dembic et al.

    Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences

    Cytokine

    (1990)
  • J.R. LaDuca et al.

    Targeting tumour necrosis factor αnew drugs used to modulate inflammatory diseases

    Dermatol Clin

    (2001)
  • M. Sugano et al.

    Increased proliferation of endothelial cells with overexpression of soluble TNF-α receptor I gene

    Atherosclerosis

    (2002)
  • D.M. Knight et al.

    Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

    Mol Immunol

    (1993)
  • B.J. Scallon et al.

    Chimeric anti-TNF-α monoclonal anti-body cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

    Cytokine

    (1995)
  • C.J. Oh et al.

    Treatment with anti-tumor necrosis factor-α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

    J Am Acad Dermatol

    (2000)
  • U. Chaudhari et al.

    Efficacy and safety of infliximab monotherapy for plaque-type psoriasisa randomized trial

    Lancet

    (2001)
  • P.J. Mease et al.

    Etanercept in the treatment of psoriatic arthritis and psoriasisa randomised trial

    Lancet

    (2000)
  • Cited by (81)

    • Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?

      2022, European Journal of Pharmacology
      Citation Excerpt :

      In psoriatic skin, dermal macrophages, dendritic cells, T cells and keratinocytes are rich sources of TNFα (Schottelius et al., 2004). It is crucial in stimulating several cytokines, chemokines and adhesion molecules in psoriasis and other autoimmune disorders involving the Th1 cascade (Ogilvie et al., 2006; Victor et al., 2003). The efficacy of TNFα inhibitors is primarily due to their role in preventing the activation of dendritic cells, which produce IL23 and activation of Th17 lineage and its effector molecules (IL17 & IL22).

    • A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis

      2018, Cytokine
      Citation Excerpt :

      Wang et al. determined that there are many infiltrated macrophages in the skin lesions and that these macrophages are an important source of TNF-α within the skin (Fig. 1). Therapeutic-based studies showed that using etanercept as a potent TNF-α signaling blocker drug could be an effective agent in the treatment of human PsO because it improved psoriasiform skin inflammation, reduced the numbers of macrophages in skin lesions, and decreased the production of TNF-α by macrophages [62,63]. To more precisely assess the involvement of macrophages, Wang et al. [60] used clodronate liposomes to deplete the macrophages from the skin lesions.

    • Integrative methylome and transcriptome analysis to dissect key biological pathways for psoriasis in Chinese Han population

      2018, Journal of Dermatological Science
      Citation Excerpt :

      Activation of NF-κB in keratinocytes has been reported to result in the production of multiple immune-related proteins and leads to further inflammatory response [39,40]. In addition, NF-κB acts as a central mediator which links the activated Th1 cells with the transcription of multiple genes encoded cytokines, such as TNF-α, IL-8, and IL-12 that are required for the pathogenesis of Ps [41–43]. Morphologic and metabolic alterations in PN skin, including processes of lipid metabolism, predominantly in the horny layer of the skin, have been reported decades ago [44,45], characterized by changes in phospholipid composition and levels and distribution of several hydrolytic enzymes and dehydrogenases.

    View all citing articles on Scopus
    View full text